For those 826 patients with potential follow-up of more than 3 years, tumour size > 5 cm, lymph node involvement, HR*(−)HER2(+), HR*(−)HER2(−) and non-pCR were associated with unfavourable RFS (HR > 1, P <  0.05, Table 7). The gene discussed is ERBB2; the disease is neoplasm.